BRC Group Holdings: a P/E of 0.5 that is not what it seems

Screeners show BRC Group Holdings, the former B. Riley Financial, at a P/E of 0.47 and 0.41x free cash flow. Those numbers are an artifact of one-off investment gains, asset sales and debt exchanges. The real question is what is left for common shareholders after debt, preferred stock and a large, hard-to-value investment portfolio. The answer is: more than the price, but with a very wide range.

At $5.76 on September 23, 2026, the shares trade 37.7% below my triangulated Base value of $9.24, an upside of 60.4%. The Bear value of $2.45 is 57.5% below the price, and the required margin of safety of 50% puts the maximum buy price at $4.62. For existing holders this is a hold. For new money it is a watchlist name.

Route: SF-14 Holding companies and conglomerates, a leveraged diversified financial services holding company in a special situation. Economic classification: Standard Company (4/12). Primary method: sum of the parts, operating EBITDA at a multiple less net debt and preferred stock, with a holding company discount. Secondary method: normalized common earnings. Values are present fair-value estimates, not 12-month price targets.

What BRC Group is

BRC Group combines capital markets (B. Riley Securities), wealth management, communications businesses, a consumer products segment, a direct lending platform and a large portfolio of proprietary investments. It is not a deposit-funded bank. After a severe crisis in 2024, including delayed filings and a Nasdaq delisting notice, it spent 2025 and 2026 selling assets, exchanging debt and restoring filing compliance, which it regained in January 2026.

The character of the company remains high risk. It increasingly behaves like a holding company with proprietary investments, and its $804.5 million investment portfolio cannot be treated as excess cash. That justifies lower multiples, an explicit holding company discount and a high margin of safety.

The latest quarter

In August the company called for full redemption of $142.1 million of its 6.50% notes due 2026, removing a near-term maturity. The consumer products segment still lost $5.7 million in the quarter.

Why the screen multiples mislead

First-half earnings were driven by trading and investment gains, especially $262.2 million of adjusted EBITDA in Q1, when operating adjusted EBITDA was only $34.6 million. Those gains do not repeat on schedule. The honest metric is the value of the operating businesses plus realizable investments, minus every claim ahead of common shareholders, minus a discount for opacity. Q2's $66 million of operating adjusted EBITDA is not simply annualized: the Base uses $185 million a year, below the $264 million a Q2 run rate would suggest and below the first half annualized.

Company-defined net debt already subtracts cash and the investment portfolio at book value from total debt. Investments are therefore counted once, at book, inside net debt, and not added again.

Claims ahead of common shareholders

Shares outstanding rose from 30.60 million at the end of 2025 to 40.20 million at June 30, 2026, about 31% in six months. Book value is about $3.54 per share, so the stock trades at 1.6x book.

Primary valuation: sum of the parts

Divided by 40.2 million shares, the primary Base value is $9.20.

Secondary valuation: normalized common earnings

Sustainable common earnings of $45 to $55 million at a distressed 7x to 8x give $7.84 to $10.95 per share. At the midpoints, $50 million at 7.5x gives $375 million, or $9.33 per share.

Historical cross-check

Historical multiples are structurally unreliable after asset sales, debt exchanges, a dividend cut, investment marks and heavy dilution. The stock traded above $50 in 2023 and collapsed in 2024. History supports a persistent discount, not automatic mean reversion.

Valuation triangulation

The methods diverge by only 1.4%. That convergence is less reassuring than it looks, because both depend on the same normalization of a volatile business.

What is the market already pricing in?

At $5.76, common equity is worth about $232 million. Reversing the Base bridge at 5x with the same discount, the price implies operating adjusted EBITDA of about $147 million, close to the Bear operating level. The market is pricing weaker normalized earnings, investment impairments, refinancing setbacks, further dilution and legal or regulatory risk, or a mix of all of them.

Bear, base and bull scenarios

Bear: the Q2 rebound fades, investment marks fall and refinancing gets harder, all of which reinforce each other in a leveraged holding company, so lowering both earnings and multiple is justified. Base: capital markets and wealth recovery partly persists and the balance sheet keeps stabilizing. Bull: strong capital markets, successful asset monetization and further deleveraging.

The probability-weighted value is $7.93, 37.7% above the price, even with a 35% Bear probability.

Sensitivity: sum of the parts value per share

Before any investment impairment, with the 28% discount. A 10% investment impairment removes about $1.44 per share from each cell.

How the buy price is set

Confidence C starts at a 40% margin of safety. Five points are added for leverage and five for opacity, for 50%. Half of the $9.24 Base gives a maximum buy price of $4.62. A distressed reference around $3.20 to $3.70 applies only if no new thesis-breaking event explains the fall.

Dividend

Common shares should not be owned for income. The common dividend was cut sharply during the balance sheet stress, and screeners showing past payouts are out of date. Preferred securities are separate, senior claims.

Reasons to own RILY

• Core recovery. Q2 operating adjusted EBITDA of $66 million was the best core quarter in nearly three years.
• Rapid deleveraging. Company-defined net debt fell by $341.7 million in the first half, and the 2026 notes are being redeemed.
• Real franchises. Capital markets, wealth management and communications have standalone value.
• A large discount. $5.76 is well below both the Base and the probability-weighted value.
• Optionality. Asset monetization and stronger capital markets could accelerate deleveraging.

What could go wrong?

• Refinancing. Solvency stress or forced asset sales. This is the main thesis breaker.
• Investment marks. A concentrated portfolio at book value could be worth materially less when sold.
• Dilution. The share count already rose 31% this year, and more issuance would absorb much of the upside.
• Governance and regulation. Past reporting delays and regulatory uncertainty keep the discount justified.

Management execution

Positives: sharp net debt reduction, an improved core result and restored filing compliance. Negatives: prior filing delays, major dilution, volatile investment marks and complicated adjusted accounting. Management credibility scores 8/20, mixed.

Stock Analyza scorecard

The valuation score is 72/100: a large discount to Base and converging methods, offset by a Bear value far below the price.

Confidence score

What I would watch from here

Review at each quarterly report, material financing, asset sale, legal or regulatory event, or equity issuance.

The three most important thesis breakers

1. Renewed refinancing stress.
2. A major investment impairment.
3. More than 10% additional dilution.

Adversarial review

The first draft's Base bridge reconciled, but three things were corrected. Its sensitivity table did not follow its own bridge: at 4x and 6x most cells were off by $0.40 to $0.70 per share. It rounded the weighted Base of $9.14 up to the higher primary value of $9.20, which the framework does not allow, and its secondary value of $9.00 had no stated inputs; at the midpoints of its own ranges it is $9.33. Finally, its Bear and Bull values of $2.70 and $15.10 were not derived from either method. They are now built from both, and the Bear case adds a 10% investment impairment, because investment marks are one of the main risks. The Base moved from $9.20 to $9.24, the Bear from $2.70 to $2.45, the Bull from $15.10 to $14.60 and the buy price from $4.60 to $4.62. The verdict is unchanged.

The strongest counter-argument is that the Q2 operating result may be a cyclical peak, investment marks may reverse, company-defined net debt may overstate realizable liquidity and further dilution could consume the upside. The Base already normalizes below the Q2 run rate, applies a large discount and requires a 50% margin of safety.

Every single test keeps the Base above the price, but combinations of lower EBITDA and a lower multiple can push value below it. The thesis is not robust enough for a higher confidence grade. The publication gate status is PASS_WITH_WARNING.

Final verdict: hold at $5.76, watchlist for new money

BRC Group has substantial recovery upside if the operating recovery and deleveraging continue, but common equity still carries unusually high capital structure, dilution, investment mark and governance risk.

Verdict: HOLD at $5.76, WATCHLIST for new money. Triangulated Base value $9.24, upside 60.4%, Confidence C (14/25). Required margin of safety 50%, maximum buy price $4.62.

For an existing holder with a position sized for this risk, the discount supports holding. New money waits for $4.62 or below with no new thesis-breaking event, or for proof that deleveraging continues without more dilution.

The main thesis breaker is a deterioration in asset values or refinancing capacity that reverses deleveraging and forces dilution or distressed sales.

Sources

Primary sources include BRC Group Holdings' June 2026 Form 10-Q, the Q2 2026 earnings release, the Q1 2026 earnings release and the 2025 Form 10-K. The note redemption and company overview come from a third-party market data aggregator.

The reference market price is $5.76, the September 23, 2026 close. Balance sheet figures are as of June 30, 2026.